| A tale of two antibodies: obinutuzumab versus rituximab CL Freeman, LH Sehn British journal of haematology 182 (1), 29-45, 2018 | 166 | 2018 |
| Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia R Swords, C Freeman, F Giles Leukemia 26 (10), 2176-2185, 2012 | 165 | 2012 |
| Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma CL Freeman, R Kridel, AA Moccia, KJ Savage, DR Villa, DW Scott, ... Blood, The Journal of the American Society of Hematology 134 (9), 761-764, 2019 | 109 | 2019 |
| High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology LC Chong, S Ben-Neriah, GW Slack, C Freeman, D Ennishi, A Mottok, ... Blood advances 2 (20), 2755-2765, 2018 | 90 | 2018 |
| Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions CL Freeman, F Morschhauser, L Sehn, M Dixon, R Houghton, T Lamy, ... Blood, The Journal of the American Society of Hematology 126 (24), 2646-2649, 2015 | 81 | 2015 |
| Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP CL Freeman, KJ Savage, DR Villa, DW Scott, L Srour, AS Gerrie, ... Blood, The Journal of the American Society of Hematology 137 (7), 929-938, 2021 | 73 | 2021 |
| Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach AR Hayden, P Tonseth, DG Lee, D Villa, AS Gerrie, DW Scott, ... Blood, The Journal of the American Society of Hematology 136 (24), 2803-2811, 2020 | 63 | 2020 |
| Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma JM Logue, LC Peres, H Hashmi, CM Colin-Leitzinger, AM Shrewsbury, ... Blood Advances 6 (24), 6109-6119, 2022 | 49 | 2022 |
| The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC B Collinge, S Ben-Neriah, L Chong, M Boyle, A Jiang, T Miyata-Takata, ... Blood, The Journal of the American Society of Hematology 137 (16), 2196-2208, 2021 | 41 | 2021 |
| Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population W Alduaij, B Collinge, S Ben-Neriah, A Jiang, LK Hilton, M Boyle, ... Blood, The Journal of the American Society of Hematology 141 (20), 2493-2507, 2023 | 37 | 2023 |
| Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants VH Jimenez-Zepeda, RL Heilman, RA Engel, EJ Carey, C Freeman, ... Transplantation 92 (5), 570-574, 2011 | 37 | 2011 |
| Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines AA Moccia, K Schaff, C Freeman, PJ Hoskins, RJ Klasa, KJ Savage, ... Blood advances 5 (5), 1483-1489, 2021 | 35 | 2021 |
| Immunotherapy in chronic lymphocytic leukaemia (CLL) CL Freeman, JG Gribben Current hematologic malignancy reports 11, 29-36, 2016 | 33 | 2016 |
| EPHA3 as a novel therapeutic target in the hematological malignancies N Keane, C Freeman, R Swords, FJ Giles Expert review of hematology 5 (3), 325-340, 2012 | 33 | 2012 |
| The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma K Rejeski, DK Hansen, R Bansal, P Sesques, S Ailawadhi, JM Logue, ... Journal of Hematology & Oncology 16 (1), 88, 2023 | 32 | 2023 |
| Bendamustine and rituximab as induction therapy in both transplant-eligible and-ineligible patients with mantle cell lymphoma D Villa, LH Sehn, KJ Savage, CL Toze, K Song, WD den Brok, ... Blood Advances 4 (15), 3486-3494, 2020 | 31 | 2020 |
| The role of inflammation in leukaemia. FJ Giles, J Krawczyk, M O'Dwyer, R Swords, C Freeman Advances in experimental medicine and biology 816, 335-360, 2014 | 28 | 2014 |
| Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? C Freeman, N Keane, R Swords, F Giles Expert opinion on pharmacotherapy 14 (10), 1417-1427, 2013 | 27 | 2013 |
| Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? CL Freeman, R Swords, FJ Giles Expert review of hematology 5 (1), 17-26, 2012 | 26 | 2012 |
| Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab CL Freeman, M Dixon, R Houghton, KA Kreuzer, G Fingerle-Rowson, ... Leukemia 30 (8), 1763-1766, 2016 | 22 | 2016 |
